Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Miguel Gonzalez-Velez"'
Autor:
Parminder Singh, Irbaz Bin Riaz, Cassandra N. Moore, Heidi E. Kosiorek, Renee K. Sharpsten, Andrea McNatty, Glenn A. Stewart, Steven R. Hwang, Alan H. Bryce, Thai H. Ho, Jan B. Egan, Miguel Gonzalez Velez, Brian A. Costello
Publikováno v:
Prostate Cancer and Prostatic Diseases. 25:479-483
Background Altered tumor suppressor genes (TSG-alt) in prostate cancer are associated with worse outcomes. The prognostic value of TSG-alt in metastatic, hormone-sensitive prostate cancer (M1-HSPC) is unknown. We evaluated the effects of TSG-alt on o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f64365832daca165a52053287569af35
https://doi.org/10.1038/s41391-021-00430-4
https://doi.org/10.1038/s41391-021-00430-4
Autor:
Thorvardur R. Halfdanarson, Miguel Gonzalez-Velez, Jason S. Starr, Mohamad Bassam Sonbol, Anas M. Saad
Publikováno v:
Pancreas. 50:47-53
Objective In this study, we aimed to determine the cause of death (COD) after the diagnosis of neuroendocrine tumors (NET). Methods We used the Surveillance, Epidemiology and End Results (SEER) Program to review patients diagnosed with NET during 200
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6baaff5d7d96b51c1593671a428cf5f1
https://doi.org/10.1097/mpa.0000000000001723
https://doi.org/10.1097/mpa.0000000000001723
Autor:
Nityam Rathi, Laura A. Sena, Neeraj Agarwal, Emmanuel S. Antonarakis, Amanda C. Larson, James R. Eshleman, Drew M. Pardoll, Pedro Isaacsson Velho, Alan H. Bryce, Benjamin L. Maughan, Colin C. Pritchard, Hao Wang, Ryan Ashkar, Su Jin Lim, Tamara L. Lotan, Julia Fountain, Roberto Nussenzveig, Nabil Adra, Miguel Gonzalez Velez, Emily Nizialek
Publikováno v:
The Oncologist
Background Genomic biomarkers that predict response to anti‐PD1 therapy in prostate cancer are needed. Frameshift mutations are predicted to generate more neoantigens than missense mutations; therefore, we hypothesized that the number or proportion
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32a1ae9ad6d702cb3506561bb2761034
https://doi.org/10.1002/onco.13601
https://doi.org/10.1002/onco.13601
Autor:
Grace Shaw, Pier Vitale Nuzzo, Edoardo Francini, Pietro Rosellini, Celestia S. Higano, Miguel Gonzalez-Velez, Irene Moreno-Candilejo, Francesca Crivelli, Antonio Cigliola, Richard M. Lee-Ying, Guido Francini, Lauren C. Harshman, Christopher Sweeney, Francesco Montagnani, Jesus Garcia-Foncillas, Alan H. Bryce, Jaime Rubio-Perez, Li Zhang, Roberto Petrioli, Nimira S. Alimohamed, Daniel Y.C. Heng, Carmelo Bengala
Publikováno v:
JAMA Network Open
Key Points Question Do patients receiving abiraterone acetate with prednisone as first-line therapy for the treatment of metastatic castration-resistant prostate cancer with bone metastases benefit from the addition of bone resorption inhibitors? Fin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d64af351dfc66c7c9a99a2092482287
http://europepmc.org/articles/PMC8299314
http://europepmc.org/articles/PMC8299314
Publikováno v:
JAMA Intern Med
Importance While there have been multiple assessments of clinical trials leading to anticancer drug approvals by the US Food and Drug Administration (FDA), the cumulative percentage of approvals based on trials with a limitation remains uncertain. Ob
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae267b8cc0a68b6f875599d9507b17b2
https://europepmc.org/articles/PMC7296449/
https://europepmc.org/articles/PMC7296449/
Autor:
Rafael Fonseca, Sinto Sebastian, Luke Mountjoy, Greg J. Ahmann, Miguel Gonzalez-Velez, Tania Jain, Jeremy T. Larsen, Leif Bergsagel, Marlene Girardo, Talal Hilal
Publikováno v:
Leukemia. 34(11)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d52dcf6de8aa5453d813404ecc6b7d6
https://pubmed.ncbi.nlm.nih.gov/32503975
https://pubmed.ncbi.nlm.nih.gov/32503975
Autor:
Miguel Gonzalez-Velez, Rafael Fonseca
Publikováno v:
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 40
Recent clinical trials have addressed the notion of early treatment of smoldering multiple myeloma (SMM). The results evidence improvement in progression-free survival and, in one study, overall survival. Although the treatment of SMM can be consider
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::348970c857ec3a6f5d1af729c4f71177
https://pubmed.ncbi.nlm.nih.gov/32207672
https://pubmed.ncbi.nlm.nih.gov/32207672
Autor:
Miguel Gonzalez Velez, Narjust Duma, Tariq U. Azam, Sejal Kothadia, Joleen M. Hubbard, Ronald S. Go, Thorvardur R. Halfdanarson, Alex A. Adjei, Siddhartha Yadav, Aaron S. Mansfield, Jonas Paludo, Jesus Vera Aguilera, Julian R. Molina
Publikováno v:
The Oncologist. 24:96-102
Background Early phase clinical trials evaluate the safety and efficacy of new treatments. The exclusion/inclusion criteria in these trials are usually rigorous and may exclude many patients seen in clinical practice. Our objective was to study the c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eea1388532229ac32d2706ed989799c6
https://doi.org/10.1634/theoncologist.2017-0687
https://doi.org/10.1634/theoncologist.2017-0687
Autor:
Robert D. McBane, Waldemar E. Wysokinski, Thomas Oliver, Leslie Padrnos, Adrienne Kaufman, Miguel Gonzalez-Velez, Heidi E. Kosiorek, Yael Kusne, Damon E. Houghton, Molly Klanderman
Publikováno v:
Blood
Introduction: Patients with coronavirus disease 2019 (COVID-19) have an increased risk for venous thromboembolic events. Thrombotic events contribute to the morbidity and mortality associated with COVID-19 infection, and have prompted investigation i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99549fd80c14eabe438f425617d38474
http://europepmc.org/articles/PMC8701434
http://europepmc.org/articles/PMC8701434
Autor:
Craig B. Reeder, A. Keith Stewart, Mariano Arribas, Heidi E. Kosiorek, Carlo Guerrero, Rafael Fonseca, Jeremy T. Larsen, Luke Mountjoy, P. Leif Bergsagel, Richard J. Butterfield, Miguel Gonzalez-Velez
Publikováno v:
Blood. 136:33-34
Introduction: Response assessment at day 100 post Autologous Stem Cell Transplant (ASCT) is associated with long-term relapsed free survival (RFS) and overall survival (OS) in multiple myeloma (MM). The International Myeloma Working Group (IMWG) are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd651881de8899854a42dceda8b1bc1f
https://doi.org/10.1182/blood-2020-142845
https://doi.org/10.1182/blood-2020-142845